Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.59 |
| ▸ | HTR3B | O95264 | 2/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | BPTF | Q12830 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-212 SCHEMBL29389957 | 1.00 | HTR2A (1.00) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| Mk-212 SCHEMBL3060615 | 0.98 | HTR2A (0.96) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| Mk-212 SCHEMBL12503246 | 0.96 | HTR2A (0.93) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| SCHEMBL6360772 | 0.93 | ALDH1A1 (0.87) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| Mk-212 SCHEMBL4420315 | 0.85 | HTR2A (0.73) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| SCHEMBL939716 | 0.82 | ALDH1A1 (0.70) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| Mk-212 SCHEMBL27809059 | 0.82 | HTR2C (0.68) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| SCHEMBL31558499 | 0.81 | CYP1A2 (0.68) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| SCHEMBL19673985 | 0.81 | CYP1A2 (0.68) | HTR2AHTR2CALDH1A1HTR1AKDM4E | |
| SCHEMBL1713569 | 0.79 | ALDH1A1 (0.66) | HTR2AHTR2CALDH1A1HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | claimed |
| US-20100260772-A1 | METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH LOW BONE MASS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-10-14 | — | — | US | claimed |
| JP-4312456-B2 | — | — | 2009-08-12 | — | — | JP | claimed |
| WO-2009045900-A2 | METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH LOW BONE MASS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-04-09 | — | — | WO | claimed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | claimed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | claimed |
| JP-2004510813-A | — | — | 2004-04-08 | — | — | JP | claimed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | claimed |
| US-6403651-B1 | SLEEP DISORDERS | LUMINIS PTY LIMITED (AU) | 2002-06-11 | — | — | US | claimed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | claimed |
| US-4742054-A | Treatment of mammals suffering from damage to the central nervous system | NAFTCHI NOSRAT E (US) | 1988-05-03 | — | — | US | claimed |
| US-4082844-A | ANOREXIC AGENTS | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-4082844-A | ANOREXIC AGENTS | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082844-A | ANOREXIC AGENTS | MERCK & CO., INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | HTR2A 22/4885HTR2C 38/4885ALDH1A1 784/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR2A 28/4885HTR2C 72/4885ALDH1A1 1317/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885ALDH1A1 527/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 10/4885ALDH1A1 1946/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | HTR2A 22/4885HTR2C 38/4885ALDH1A1 784/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2A 5/4885HTR2C 1/4885ALDH1A1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.